Search | Clinical Trials Finder

Conditions: Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Familial Hypercholesterolemia
Interventions: Screening for FH; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias
Interventions: Obicetrapib, Placebo; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Toluca Lake, California • Sarasota, Florida + 17 more

Conditions: Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 10
States / cities: Mission Viejo, California • Newport Beach, California • Stanford, California + 7 more

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: bempedoic acid; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio

Conditions: Familial Hypercholesterolemia
Interventions: Evolocumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: The Bronx, New York • Cincinnati, Ohio • Nashville, Tennessee

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Tucson, Arizona • New York, New York • Winston-Salem, North Carolina + 3 more

Conditions: Familial Hypercholesterolemia
Interventions: Implitapide; Drug
Lead sponsor: Medical Research Laboratories International; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Heterozygous Familial Hypercholesterolemia
Interventions: lerodalcibep; Drug
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hyperlipidemias
Interventions: Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos; Combination Product · Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more

Conditions: Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia
Interventions: CTX310; Drug
Lead sponsor: CRISPR Therapeutics AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Hialeah, Florida • Jacksonville, Florida • Orlando, Florida + 5 more

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: Placebo, Obicetrapib; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 2,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 69
States / cities: Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more

Conditions: Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions: Mipomersen Sodium; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 20
States / cities: Mission Viejo, California • Newport Beach, California • Bridgeport, Connecticut + 17 more

Conditions: Heterozygous Familial Hypercholesterolemia
Interventions: Placebo, Alirocumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Aurora, Colorado • Hartford, Connecticut • Kansas City, Kansas + 4 more

Conditions: Heterozygous Familial Hypercholesterolaemia
Interventions: AZD0780, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Garden Grove, California • San Diego, California • Miami Lakes, Florida + 16 more

Conditions: Hypercholesterolemia
Interventions: Bempedoic acid; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • West Covina, California • Boca Raton, Florida + 5 more

Conditions: Heterozygous or Homozygous Familial Hypercholesterolemia
Interventions: Inclisiran; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 5
States / cities: Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 2 more

Conditions: Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Interventions: Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo; Combination Product · Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 45
States / cities: Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 17
States / cities: Huntsville, Alabama • Mission Viejo, California • Newport Beach, California + 14 more

Conditions: Hypercholesterolemia, Familial Hypercholesterolemia
Interventions: Enlicitide Decanoate, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 13
States / cities: Daphne, Alabama • Boca Raton, Florida • Cutler Bay, Florida + 10 more

Conditions: Heterozygous Familial Hypercholesterolemia
Interventions: Evolocumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 12
States / cities: Farmington, Connecticut • Wilmington, Delaware • Iowa City, Iowa + 9 more

Conditions: Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
Interventions: Alirocumab, Placebo Matched to Alirocumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 11
States / cities: Mission Viejo, California • Newport Beach, California • Thousand Oaks, California + 8 more

Conditions: ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions: Inclisiran Sodium; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 141
States / cities: Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions: ETC-1002, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more

Search by objective public record fields.

The ORIGIN-FH Study

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)